Puma Biotechnology
PBYI
88 hedge funds and large institutions have $75.2M invested in Puma Biotechnology in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 34 reducing their positions, and 31 closing their positions.
43% more call options, than puts
Call options by funds: $231K | Put options by funds: $161K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10.4% less ownership
Funds ownership: 72.41% → 62.01% (-10%)
12% less capital invested
Capital invested by funds: $85.9M → $75.2M (-$10.7M)
15% less funds holding
Funds holding: 104 → 88 (-16)
41% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 34
45% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.73M |
| 2 |
Millennium Management
New York
|
+$758K |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$584K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$540K |
| 5 |
Morgan Stanley
New York
|
+$529K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.67M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.14M |
| 3 |
SO
STRS Ohio
Columbus,
Ohio
|
-$682K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$591K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$570K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
101
American International Group
New York
| – | -$46K | -16,026 | Closed |
|
102
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| – | -$41K | -14,189 | Closed |
|
103
Invesco
Atlanta,
Georgia
| – | -$34K | -11,855 | Closed |
|
104
ProShare Advisors
Bethesda,
Maryland
| – | -$29K | -10,284 | Closed |
|
|
ECM
105
ExodusPoint Capital Management
New York
| – | -$29K | -10,077 | Closed |
|
|
AB
106
Amalgamated Bank
New York
| – | -$15K | -5,256 | Closed |
|
107
Legal & General Group
London,
United Kingdom
| – | -$10K | -3,554 | Closed |
|
108
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$9K | -3,044 | Closed |
|
|
AIP
109
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$7K | -2,522 | Closed |
|
|
MAM
110
Meeder Asset Management
Dublin,
Ohio
| – | -$6K | -2,078 | Closed |
|
|
ACM
111
Aquatic Capital Management
Chicago,
Illinois
| – | -$2K | -600 | Closed |
|
|
CS
112
Credit Suisse
Zurich,
Switzerland
| – | +$42 | +17 | New |
|
|
EI
113
Ellevest Inc
New York
| – | +$234 | +94 | New |
|
PBYI Hedge Fund Activity: Q2 2022 in Review
88 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2022, worth a combined $75.2M — down 12% from $85.9M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of PBYI and 17 opened new positions — a net loss of 14 holders — while 34 trimmed existing stakes and 20 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.73M. The largest seller was BlackRock, cutting an estimated $3.67M.
- 88 institutional investors held Puma Biotechnology (PBYI) as of Q2 2022, down from 104 in Q1 2022.
- Funds reported $75.2M of Puma Biotechnology stock for Q2 2022, down 12% quarter-over-quarter.
- 17 funds opened new Puma Biotechnology positions in Q2 2022 and 31 closed out, a net change of -14 holders.
- The largest Puma Biotechnology buyer in Q2 2022 was Armistice Capital, an estimated $3.73M added.
- The largest Puma Biotechnology seller in Q2 2022 was BlackRock, an estimated $3.67M sold.
Based on aggregated 13F filings for Q2 2022.